MAP Kinase Signaling
Phospho-MEK1/2 (Ser221) Blocking Peptide
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1210S | 100 μg | 16,000 | |
|
MEK1/2抗体製品一覧
| 使用目的 | |
| Phospho-MEK1/2 (Ser221) (166F8) Rabbit mAb (#2338) の反応をブロックし、抗体の反応特異性を確認するために使用 |
Western Blotting

Western Blot analysis of extracts from NIH/3T3 cells, untreated or serum-treated, using Phospho-MEK1/2 (Ser221) (166F8) Rabbit mAb #2338 (left) or same antibody preincubated with Phospho-MEK1/2 (Ser221) Blocking Peptide (right)
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Phospho-MEK1/2 (Ser221) (166F8) Rabbit mAb #2338 in the presence of control peptide (left) or Phospho-MEK1/2 (Ser221) Blocking Peptide (right).
MEK1 and MEK2, also called MAPK or Erk kinases, are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation (1-3). Activation of MEK1 and MEK2 occurs through phosphorylation of two serine residues at positions 217 and 221, located in the activation loop of subdomain VIII, by Raf-like molecules. MEK1/2 is activated by a wide variety of growth factors and cytokines and also by membrane depolarization and calcium influx (1-4). Constitutively active forms of MEK1/2 are sufficient for the transformation of NIH/3T3 cells or the differentiation of PC-12 cells (4). MEK activates p44 and p42 MAP kinase by phosphorylating both threonine and tyrosine residues at sites located within the activation loop of kinase subdomain VIII.
-
Crews, C.M. et al. (1992) Science 258, 478-480.
-
Alessi, D.R. et al. (1994) EMBO J. 13, 1610-1619.
-
Rosen, L.B. et al. (1994) Neuron 12, 1207-1221.
-
Cowley, S. et al. (1994) Cell 77, 841-852.